Floatz Rating
B57/100
Confidence
Indicative
Sponsor
BlackThorn Therapeutics, Inc.
Modality
Small molecule
Development Phase
Phase 2
Status
Dormant
Evidence ledger · v0.2
Clinical Evidence
Clinical track record: trial progression, reported outcomes, safety signals, and endpoint quality.
42Moderate confidence
Detailed axis rationale is planned and will be published soon.
| Trial | Phase | Status | N | Primary endpoint | Readout |
|---|---|---|---|---|---|
NCT03608371CT.gov BTRX-246040 Study in Participants With Parkinson's Disease With Motor Fluctuations | — | Completed | — | — | — |
Competitive Position
Competitive setting: how crowded the indication is, class-level failures, and timing against rivals.
95High confidence
Detailed axis rationale is planned and will be published soon.
Same indication · Movement Disorder
| Asset | Sponsor | Phase | Rating |
|---|---|---|---|
| LY-2940094 (this asset) | BlackThorn Therapeutics, Inc. | P2 | B · 57 |
| Levodopa | MDD US Operations, LLC a subsidiary of Supernus Pharmaceuticals | P4 | BBB |
| Trimethobenzamide | MDD US Operations, LLC a subsidiary of Supernus Pharmaceuticals | P4 | BB |
| 1H-INDOLE-1-CARBOXYLIC ACID, OCTAHYDRO-4-HYDROXY-4-((3-METHYLPHENYL)ETHYNYL)-, METHYL ESTER, (3AR,4S,7AR)- | Novartis Pharmaceuticals | P2 | BB |
| Apomorphinum | MDD US Operations, LLC a subsidiary of Supernus Pharmaceuticals | P4 | BB |
| Live Combined Bifidobacterium | Beijing Friendship Hospital | P4 | BB |
| Lemborexant | YangPan | P4 | BB |
| Live Combined Bifidobacterium,Lactobacillus And Enterococcus Capsules | Beijing Friendship Hospital | P4 | BB |
| Maolactin | RDC Clinical Pty Ltd | P3 | BB |
+16 more in the Movement Disorder cohort
Other indications for LY-2940094
| Indication | Sponsor | Phase | Rating |
|---|---|---|---|
| Major Depressive Disorder | — | P2 | B · 58 |
| Anxiety Disorder | — | P2 | CCC · 53 |
| Parkinson Disease | — | P2 | CCC · 51 |
Scientific Foundation
Strength of the underlying biology: target validation, tractability, modality fit, and how related mechanisms have fared.
NR
Planned for methodology v0.2.
Development Feasibility
How realistically the program can be executed, drawing on modality precedent, enrollment dynamics, and sponsor delivery.
NR
Planned for methodology v0.2.
Commercial Opportunity
Commercial prize: addressable population, unmet need, and the value case for the indication.
NR
Planned for methodology v0.2.
IP & Exclusivity
Exclusivity position, covering patent protection and freedom-to-operate runway.
NR
Planned for methodology v0.2.
Manufacturing & Supply
Manufacturing and supply readiness, driven by modality process and scale-up risk.
NR
Planned for methodology v0.2.
Related assets
- LevodopaMDD US Operations, LLC a subsidiary of Supernus PharmaceuticalsBBB
- TrimethobenzamideMDD US Operations, LLC a subsidiary of Supernus PharmaceuticalsBB
- 1H-INDOLE-1-CARBOXYLIC ACID, OCTAHYDRO-4-HYDROXY-4-((3-METHYLPHENYL)ETHYNYL)-, METHYL ESTER, (3AR,4S,7AR)-Novartis PharmaceuticalsBB
- ApomorphinumMDD US Operations, LLC a subsidiary of Supernus PharmaceuticalsBB
- Live Combined BifidobacteriumBeijing Friendship HospitalBB
Citation
Floatz Terminal. LY-2940094 in Movement Disorder. Methodology v0.2. Rated under v0.2 effective July 8, 2026. Last refreshed July 8, 2026. Accessed July 14, 2026. https://terminal.floatz.ai/assets/ly-2940094-movement-disorder
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →